

## 36th Annual Medical & Scientific Conference

### Lipids - the best yet

Wednesday 5 - Friday 7 July 2023 | University of Warwick (Coventry)

## Programme

British Dietetic Association endorsed (BDA endorsement applies only to the educational content of the learning activity)

CPD approved via the Federation of the Royal Colleges of Physicians of the United Kingdom for 11 category 1 (external) CPD credit(s)

### Tuesday 4 July

Time		Topic	Venue location
16:00 – 18:30	Invited participants only	<b>HEART UK Board meeting</b> Chaired by: <a href="#">Jules Payne + Pete Green</a> <i>Invited attendees only - CPD is not applicable</i>	Radcliffe House - Rad space 12
18:00 - 22:00		EXHIBITION BUILD	Oculus foyer
18:45 - 19:15	Invited guests only	<b>HEART UK - meet the team</b> Hosted by: <a href="#">Jules Payne</a>	Radcliffe House lounge area - ground floor (raised area by the bar)
19:30	Invited guests only	<b>HEART UK + informal speaker dinner</b> Hosted by: <a href="#">Jules Payne</a>	Radcliffe House private dining room 2 (by bar)

### Wednesday 5 July

Time		Topic	Speaker	Venue location
07:00 - 09:00		Breakfast ( <i>Bluebell House residential guests only</i> )		Rootes Building - 1st floor restaurant
08:30		Registration opens		Oculus foyer
09:00 - 11:00	Invited participants only	<b>HEART UK MS&amp;R Committee meeting</b> Chaired by: <a href="#">Prof Handrean Soran</a> <i>Invited attendees only - CPD is not applicable</i>		Oculus room OC 1.01 - 1st floor
11:00 - 11:15		Comfort break		
11:15 - 12:30	Invited participants only	<b>Lipid Interest group meeting</b> Chaired by: <a href="#">Ms Alison Pottle</a> <i>CPD is not applicable to this meeting</i>		Oculus room OC 0.02 - grnd floor

11:00 - 12:20		Registration   Networking   Exhibition		Oculus foyer
11:45 - 12:20		Lunch		Oculus foyer
12:20 - 12:30	Livestream	<b>Chairman's Welcome</b>	<b>Dr Peter Green</b> (Chair, HEART UK)	Oculus LT 1.05 - 1st floor
12:30 - 12:40	Livestream	<b>A tribute to the life of Prof Barry Lewis</b>	<b>Dr Alan Rees</b>	Oculus LT 1.05 - 1st floor
	Livestream	<b>SESSION ONE   The National Picture</b>		
		Co-chairs: <b>Pete Green + Dev Datta</b>		
12:40 - 13:00		<b>Plenary speaker</b> <b>General update on the National Perspective</b>	<b>Dr Shahed Ahmad</b> (London)	Oculus LT 1.05 - 1st floor
13:00 - 13:20		<b>Plenary speaker</b> <b>The AHSN Lipid and FH national Programme: Taking a joined up approach to cardiovascular disease prevention</b> The impact of the national programme towards NHS CVD LTP ambitions	<b>Dr Joe Chidanyika</b> (Newcastle upon Tyne)	Oculus LT 1.05 - 1st floor
13:20 - 13:40		<b>Plenary speaker</b> <b>CVDPREVENT</b> An update on the National CVDPREvent Audit and opportunities for lipid optimisation	<b>Dr Peter Green</b> (Kent)	Oculus LT 1.05 - 1st floor
13:40 - 13:55		Group discussion		
13:55 - 14:25		Refreshments   Networking   Exhibition		Oculus foyer
	Livestream	<b>SESSION TWO   Impact of multiple treatments</b>		
		Co-chairs: <b>Tina Khan + Handrean Soran</b>		
14:25 - 14:45		<b>Plenary speaker</b> <b>Cardiovascular disease prevention and clinical trials</b>	<b>Prof Azfar Zaman</b> (Newcastle)	Oculus LT 1.05 - 1st floor
14:45 - 14:55		Discussion		
14:55 - 15:15		<b>Plenary speaker</b> <b>Lipids, inflammation and biologics</b>	<b>Prof Ernest Choy</b> (Cardiff)	Oculus LT 1.05 - 1st floor VIRTUAL
15:15 - 15:25		Discussion		
15:25 - 16:00		Refreshments   Networking   Exhibition		Oculus foyer
		<b>SESSION THREE - sponsored symposia</b>		
16:00 - 16:40	Livestream	<b>Symposia session 1</b> <b>Two decades of PCSK9: from discovery to making the case for change in UK lipid management</b> Join <b>Professor Derek Connolly</b> who will be telling the story of PCSK9 – from discovery to consensus on lipid management in the UK  <b>Sponsored by Amgen</b> <i>Sponsored symposia sessions are not CPD accredited directly by HEART UK. This Amgen sponsored symposium is intended for UK healthcare professionals only. This promotional symposium is organised and funded by Amgen.</i>	16:00 – 16:05 Welcome and introduction Chair - <b>Dr Nigel Capps</b>  16:05 – 16:30 The story of PCSK9 & reaching a consensus on lipid management <b>Professor Derek Connolly</b> , Consultant Cardiologist, Birmingham UK  16:30 – 16:40 Q&A	Oculus LT 1.05 - 1st floor
16:40 - 16:50		Changeover		

16:50 - 17:30	Livestream	<p><b>Symposia session 2</b>  <b>Optimising cardiovascular risk reduction in stable statin-treated patients</b>  Main highlights from the REDUCE-IT trial, Real life case studies and practical learnings.</p> <p><b>Sponsored by Amarin</b>  <i>Sponsored symposia sessions are not CPD accredited directly by HEART UK. This symposium contains promotional content and is organised and funded by Amarin Pharmaceuticals Ireland Limited. For healthcare professionals located in Great Britain and Northern Ireland only.</i></p>	<p><b>Dr Ahai Luvai</b>, Consultant in Metabolic Medicine, Newcastle Hospitals NHS Foundation Trust</p> <p><b>Dr Yee Ping Teoh</b>, Consultant Chemical Pathologist, Wrexham Maelor Hospital</p>	Oculus LT 1.05 - 1st floor
17:30 - 17:40		Comfort break		
17:30 - 18:30		Check into accommodation		
17:40 - 18:40	Livestream	<p>17:40 - 18:40  <b>Hyperlipidaemia Education Study session</b>  <i>Oculus LT 1.05 - 1st floor</i></p> <p><b>Session co-chairs   Prof Handrean Soran + Dr Bilal Bashir</b></p> <p>17:40 - 18:00  <b>A critical review of previous fibrate studies</b>  It has taken 60 years of controversy and misunderstanding to understand how fibrates decrease CHD risk  <b>Prof Paul Durrington</b> (Manchester)</p> <p>18:00 - 18:10 Discussion</p> <p>18:10 - 18:30  <b>Recent triglyceride lowering RCTs and their clinical implications</b>  <b>Prof Handrean Soran</b> (Manchester)</p> <p>18:30 - 18:40 Discussion</p>	<p>17:40 - 18:10  <b>HEART UK AGM</b>  Chaired by: <b>Jules Payne + Pete Green</b>  <i>Oculus room OC 1.01 - 1st floor</i></p> <p><i>CPD is not applicable to this session</i></p>	2 x 20 mins pres + 10 mins Q&A
18:30 - 19:10	In person only	<p><b>FH and allied health professional networking session</b>  This is a networking session where FH nurses and allied health care professionals working with familial hypercholesterolaemia can meet and share best practice, information on current projects (national or local) or ask for advice about any issues or barriers they are experiencing in their work. We are a supportive group and welcome all newcomers to the field of FH work.  Hosted by: <b>Lisa Gritzmacher</b>  <i>CPD is not applicable to this session</i></p>		Oculus - 0.02 grnd floor
18:30 - 19:30	In person only	<p><b>Spotlight on posters - meet the authors</b>  An informal session where the audience can meet all the poster authors to discuss their work. This session is unjudged.  <i>See poster listing at end of programme</i></p>		Oculus - 1st floor landing
18:30 - 21:30		<b>Welcome and buffet reception</b>		Oculus foyer
19:30:00		Chairman's welcome   <b>Dr Pete Green</b> Premium sponsor welcome   <b>Amgen</b> Presentation of the Rianna Wingett award by <b>Dr Pete Green</b>		
21:30:00		Evening ends		

Time		Topic	Speaker	Venue location
07:00 - 09:00		Breakfast ( <i>Bluebell House residential guests only</i> )		Rootes Building - 1st floor restaurant
08:00 - 09:00	Invited participants only	<b>Healthcare committee meeting</b> Chaired by: <a href="#">Michaela Nuttall</a> <i>Invited attendance only - CPD is not applicable</i>		Oculus room OC 1.01 - 1st floor
08:30		Registration opens		Oculus foyer
08:30 - 09:20		Refreshments   Networking   Exhibition		Oculus foyer
09:20 - 09:25		<b>Opening remarks</b>	<a href="#">Dr Dev Datta</a>	Oculus LT 1.05 - 1st floor
	<b>Livestream</b>	<b>SESSION FOUR   Paediatrics</b>		
		Co-chairs: <a href="#">Lorraine Priestley-Barnham</a> + <a href="#">Nigel Capps</a>		
09:25 - 09:45		<b>Plenary speaker</b> <b>Paediatric FH: Reflections from the past, innovations of the present and visions for the future</b>	<a href="#">Mrs Lorraine Priestley-Barnham</a> (Harefield, UK)	Oculus LT 1.05 - 1st floor
09:45 - 10:05		<b>Plenary speaker</b> <b>Slovenian experience of screening children for FH</b> Presentation of the Slovenian 3-step program of FH screening in a young children and their families	<a href="#">Prof Urh Grošelj</a> (Ljubljana, Slovenia)	Oculus LT 1.05 - 1st floor
10:05 - 10:25		<b>Plenary speaker</b> <b>Reviving the Paediatric FH Register – a 5-year NIHR study</b> Using clinical and patient-reported data, a new 5-year funded NIHR Health Technology Assessment project will assess the clinical and cost-effectiveness of starting familial hypercholesterolaemia treatment in childhood, providing evidence to support clinical guidelines on what age and lipid levels paediatric patients should start lipid lowering treatment.	<a href="#">Dr Laila Tata</a> (Nottingham)	Oculus LT 1.05 - 1st floor
10:25 - 10:35		<b>Interactive case study session</b>		
10:35 - 10:45		Panel discussion and Q&A		
10:45 - 11:15		Refreshments   Networking   Exhibition		
	<b>Livestream</b>	<b>SESSION FIVE   Practicalities of Diet and Lifestyle in Lipid Management</b>		

		<p>Chair: <a href="#">Lynne Garton</a>, Dietetic Adviser at HEART UK</p> <p><b>11:15 - 12:05</b>  <b>Session 1: Panel Discussion Considering Dietary Aspects Impacting Lipid Results</b>  Using case studies with different lipid scenarios, the Panel will provide insights into the nutritional aspects needing to be considered when evaluating lipid results, along with practical dietary recommendations to give to patients.</p> <p><b>12:05 - 12:25</b>  <b>Session 2: Putting this into Practice – HEART UK’s CVD Diet Checklist</b>  All guidelines for lipid management recommend advising on a heart healthy eating pattern. However, this can be achieved in a variety of ways. To address this, HEART UK has designed a Cardiovascular diet checklist to help assess the quality of a patient’s diet and determine where improvements can be made. This session will highlight the development of the tool and the practical applications.</p>	<p>Panellists:  <a href="#">Dr Alan Flanagan</a>, University of Surrey  <a href="#">Dr Kofi Antwi</a>, Specialist Registrar, University of Bristol</p> <p><a href="#">Ms Elphee Medici</a>, Consultant Nutritionist</p>	
11:15 - 12:25				Oculus LT 1.05 - 1st floor
12:25 - 13:30		Lunch   Networking   Exhibition		Oculus foyer
12:25 - 13:30	Invited participants only	<p><b>Simon Broome committee meeting</b>  Chaired by: <a href="#">Nigel Capps</a>  <i>Invited attendees only - CPD is not applicable</i></p>		Oculus room OC 1.01 - 1st floor
12:30 - 12:40	In person only	<p>Premium sponsor "Meet the expert"  Hosted on the Amgen stand - informal Q&amp;A</p>		Amgen stand
12:45 - 13:15	In person only	<p><b>Lunch and Learn</b>  <b>Meet the Experts</b>  <b>Practical advice and top tips for writing and creating abstracts</b>  Using real work examples to identify best practice for abstract submissions  <i>CPD is not applicable to this session</i></p>	Run by   <a href="#">Lorraine Priestley-Barnham</a> , <a href="#">Tina Khan</a> , <a href="#">Peter Penson</a> , <a href="#">Andreas Tridimas</a>	Oculus mtg OC 0.02 - grnd floor
	<b>Livestream</b>	<b>SESSION SIX</b>		
		Co-chairs: <a href="#">Jai Cegla</a> + <a href="#">Mike Khan</a>		
13:30 - 13:55		<p><b>Plenary speaker</b>  <b>Lipid Education and learning from inappropriate referrals</b>  <b>Lessons from the Harefield experience</b>  Sharing our experience in managing cardiovascular risk factors including lipid conditions in the primary and secondary prevention of cardiovascular disease- Lessons from a tertiary cardiac centre</p>	<p><a href="#">Prof Gordon Ferns</a> (Brighton)  <a href="#">Dr Tina Khan</a> (Harefield)</p>	Oculus LT 1.05 - 1st floor
13:55 - 14:05		Discussion		
14:05 - 14:30		<p><b>Plenary speaker</b>  <b>Cardiac CT and emerging research</b></p>	<a href="#">Dr Tarun Mittal</a> (Harefield)	Oculus LT 1.05 - 1st floor
14:30 - 14:40		Discussion		
14:40 - 15:30		Refreshments   Networking   Exhibition		Oculus foyer
	<b>Livestream</b>	<p><b>SESSION SEVEN</b>  <b>Abstracts of free communications   Medical &amp; Scientific</b>  Oculus LT 1.05 - 1st floor</p>	<p><b>SESSION SEVEN</b>  <b>Abstracts of free communications   Primary &amp; Healthcare</b>  Oculus LT 0.03 - ground floor</p>	
		Co-chairs: <a href="#">Liz Hughes</a> + <a href="#">Andreas Tridimas</a>	Co-chairs: <a href="#">Michaela Nuttall</a> + <a href="#">Alison Pottle</a>	

15:30 - 15:40		<b>FC 1</b> Patient demographics and clinical characteristics among patients with a premature myocardial infarction and lipoprotein(a) measurement: a retrospective analysis of the South Tyneside and Sunderland NHS Foundation Trust in the UK <a href="#">Peter Carey</a> (South Shields)	<b>FC 6</b> Familial Chylomicronaemia Syndrome (FCS) Compared to Multifactorial Chylomicronaemia Syndrome (MCS) – Lessons learnt from United Kingdom FCS Registry <a href="#">Bilal Bashir</a> (Manchester)	
15:40 - 15:45		Discussion	Discussion	
15:45 - 15:55		<b>FC 2</b> Lomitapide hepatic safety: A long-term retrospective analysis in patients with homozygous familial hypercholesterolaemia <a href="#">Jai Celga</a> (London)	<b>FC 7</b> Elevated lipoprotein(a) levels in Familial Hypercholesterolaemia (FH): prevalence and implications for FH clinical diagnosis <a href="#">Alessia David</a> (London)	
15:55 - 16:00		Discussion	Discussion	
16:00 - 16:10		<b>FC 3</b> Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank <a href="#">Marta Futema</a> (London)	<b>FC 8</b> Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation <a href="#">Rob Gingell</a> (Rhyl)	
16:10 - 16:15		Discussion	Discussion	
16:15 - 16:25		<b>FC 4</b> How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition? <a href="#">Kate Haralambos</a> (Cardiff)	<b>FC 9</b> Impact of a pharmacist-led clinic in optimising lipid therapy for secondary prevention in vascular and diabetic foot patients <a href="#">Matthew Hart</a> (Newcastle)	
16:25 - 16:30		Discussion	Discussion	
16:30 - 16:40		<b>FC 5</b> Rationale, preclinical data, and study design of the heart-1 clinical trial – a first-in-human Phase 1b study of an in vivo base editing therapy targeting the PCSK9 gene in the liver <a href="#">Scott Vafai</a> (Boston, USA)	<b>FC 10</b> Real-world experience with inclisiran: 12 month data from the Hammersmith Hospital Lipid Clinic <a href="#">Emma Jackson</a> (London)	
16:40 - 16:45		Discussion	Discussion	
16:45 - 17:05		Refreshments   Networking   Exhibition		Oculus foyer
	<a href="#">Livestream</a>	<b>SESSION EIGHT</b>		
		Chair: <a href="#">Handrean Soran</a>		
17:05 - 18:05		<b>Keynote Myant lecture:</b> Familial hypercholesterolemia and PCSK9: from genetics to clinical trials The history of a multipronged paradigm shift that provided answers but also shifted the knowledge of FH genetics.	<a href="#">Prof Catherine Boileau</a> (Paris, FRANCE)	
18:05 - 18:10		Day two closing remarks		Oculus LT 1.05 - 1st floor
19:00 - 19:30		Pre dinner drinks reception		Panorama Suite (2nd floor, Rootes Building)
19:30 - 23:30		Black and White Conference dinner		Panorama Suite (2nd floor, Rootes Building)

## Friday 7 July

Time		Topic	Speaker	Venue location
07:00 - 09:00		Breakfast (Bluebell House residential guests only)		Rootes Building - 1st floor restaurant
08:30		Registration opens		Oculus foyer
08:00 - 09:00	Invited participants only	<b>Apheresis Working Group committee meeting</b> Chaired by: <a href="#">Prof Dev Datta</a> <i>Invited attendees only - CPD is not applicable to this session</i>		Oculus room OC 0.02 - grnd floor
08:30 - 09:30		Refreshments   Networking   Exhibition		Oculus foyer
08:50 - 09:50	In person only	<b>Spotlight on posters session</b>		Oculus first floor landing
		<b>Moderated only</b>		
		Judges   <a href="#">Safwan Adam</a> , <a href="#">Tina Khan</a> , <a href="#">Ahai Luvai</a> , <a href="#">Peter Penson</a>		
		MP1 Should the Sampson LDL cholesterol equation replace the Friedewald equation in routine clinical practice? A comparison of three equations against a beta quantification method <a href="#">Muhammad Abbas</a> (Newcastle)		
		MP2 Determinants of lipid clinic referral and attendance in a multi-ethnic adult population in South London <a href="#">Aya Ayoub</a> (London)		
		MP3 Familial Chylomicronaemia Syndrome (FCS) Score Validation in United Kingdom FCS Registry: Can Additional Variables Improve the FCS Score Performance? <a href="#">Bilal Bashir</a> (Manchester)		
		MP4 Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients - Results from the efficacy phase of the APH-19 study <a href="#">Tracy Cunningham</a> (Reus, Spain)		
		MP5 How many FH genetic tests were performed by the UK Genetic Laboratory Hubs in 2022? <a href="#">Steve Humphries</a> (London)		
		MP6 Statin treatment is associated with greater hyperglycaemic response to a glucagon challenge <a href="#">Ben Jones</a> (London)		
		MP7 A cross-sector, multidisciplinary approach to lipid optimisation <a href="#">Marcus Jones</a> (Gloucester)		
		MP8 Cardiovascular Disease Risk Estimation in Mutation Confirmed Familial Hypercholesterolaemia <a href="#">Ekitumi Ofagbor</a> (London)		
		MP9 NHS North Thames Genomic Medicine Service Alliance (NHS NTGMSA) Pilot: Implementing UCLPartners Proactive Care Framework for Familial Hypercholesterolaemia Screening and Cascade Testing in Primary Care <a href="#">Dominic Studart</a> (London)		

		MP10 Preclinical data supporting the potential efficacy and safety of VERVE-201 – an investigational in vivo base editing medicine designed in inactivate the ANGPTL3 gene in the liver <a href="#">Scott Vafai</a> (Boston, USA)	
09:50 - 10:00		Comfort break	
		<b>SESSION NINE - sponsored symposia</b>	
10:00 - 10:40	<b>Livestream tbc</b>	<b>Symposia session 3</b> <b>Simplifying the lipid management pathway for primary and secondary care</b> Dr Elnaggar will discuss how he has locally set up clear referral and treatment management pathways between primary and secondary care, increased awareness of LDL-C targets, and ensured that valid referrals are being obtained so that high-risk patients can be prioritised.  <b>Sponsored by Sanofi</b> <i>Sponsored symposia sessions are not CPD accredited directly by HEART UK. This symposium is intended for UK healthcare professionals only. This symposium is organised and funded by Sanofi.</i>	<b>Dr Adie Viljoen</b> , Consultant Chemical Pathologist, East and North Hertfordshire NHS Trust Hon. Consultant, Cambridge University Hospitals NHS Foundation Trust  <b>Dr Mohamed Elnaggar</b> , Consultant Endocrinologist and Lipidologist, Head of Lipid Service, University Hospitals of Morecambe Bay NHS Foundation Trust  Oculus LT 1.05 - 1st floor
10:40 - 10:50		Changeover	
10:50 - 11:30	<b>Livestream</b>	<b>Symposia session 4</b> <b>A stepwise approach to lipid management – What more can specialist services do to support primary care?</b> The presentation will discuss how specialist services can support primary care and the role of oral combination lipid lowering therapy in the management of elevated cholesterol.  <b>Sponsored by Daiichi Sankyo</b> <i>Sponsored symposia sessions are not CPD accredited directly by HEART UK. This symposium is intended for UK healthcare professionals only. This promotional meeting has been organised and funded by Daiichi Sankyo UK</i>	10.50 <sup>2</sup> Open session  10:55 <sup>2</sup> A stepwise approach to lipid management – What more can specialist services do to support primary care? <b>Dr Adie Viljoen</b> , Consultant Chemical Pathologist Physician, East and North Hertfordshire NHS Trust Honorary Consultant, Cambridge Universities NHS Trust  11:15 <sup>2</sup> Questions & answers  11.20 <sup>2</sup> Session close  Oculus LT 1.05 - 1st floor
11:30 - 11:50	<b>Livestream</b>	Refreshments   Networking   Exhibition	Oculus foyer
		<b>SESSION TEN</b>	
11:50 - 13:10		<b>Clinical Lipidology Live</b> Live patient case studies and discussion	Facilitator: <b>Dev Datta</b> Panel members: Case study authors in audience  Oculus LT 1.05 - 1st floor
13:10 - 13:20	<b>Livestream</b>	<b>Presentation of prizes and awards</b> <b>Closing remarks</b>	<b>Dr Pete GREEN</b> (chair - HEART UK)

### Unmoderated posters

Networking session | Wed 5 July | 18:30-19:30 hrs

P11

Elevated lipoprotein(a) associated with an acute thromboembolic myocardial infarction  
[Sameeha Al-Sayed](#) (London)



---

P12	Specific removal of oxidized cholesterol with a cyclodextrin dimer drug candidate towards reversing atherosclerosis <a href="#">Amelia Anderson</a> (Novato, USA)
P13	Differences in perceptions towards lipid management guidelines amongst general practitioners and specialist prescribers <a href="#">Vivian Auyeung</a> (Brighton)
P14	South West London Lipids Transformation Programme: Its impact and our learning <a href="#">Pedro Bandeira</a> (London)
P15	Optimising Lipid Service- a Quality Improvement Project <a href="#">Purba Banerjee</a> (Newcastle)
P16	Isn't it time that we all started singing from the same hymn sheet? <a href="#">Charis Browne</a> (London)
P17	Analysis of biological variability in lipid analytes within a cohort of paediatric neurology patients undergoing ketogenic diet <a href="#">Nathan Cantley</a> (Bristol)
P18	Effects of dolutegravir therapy on lipid metabolism in HIV positive people in Southern Africa <a href="#">Rudo Chakanetsa</a> (Harare, Zimbabwe)
P19	Identifying high cholesterol in the ambulance setting: impact of a primary prevention programme to tackle health inequality <a href="#">Karl Charlton</a> (Newcastle)
P20	Applying the new (Simpson) phenotypic classification system for dyslipidemias based on the standard lipid profiles from a low resourced African country <a href="#">Itai Chitungo</a> (Harare, Zimbabwe)
P21	SLCO1B1 polymorphisms and different statin agents' intolerance in Familial hyperlipidemia patients – Practice review <a href="#">Omar Elboraey</a> (Chorley)
P2	Development of the One Gloucestershire primary care based familial hypercholesterolaemia case-finding and referral pathway <a href="#">Kok-Swee Gan</a> (Gloucester)
P23	Impact of COVID 19 pandemic in Wales on lipid clinic referrals from primary care <a href="#">Nader Genedy</a> (Cardiff)
P24	A best practice response to the PCN DES FH indicator (IIF CVD-04); example from West Midlands and Wessex FH Services <a href="#">Elaine George + Melanie Watson</a> (Birmingham)
P25	Experience of DES CVD familial hypercholesterolaemia case finding in Bristol <a href="#">Lisa Gritzmacher</a> (Bristol)
P26	Evaluation of low-density lipoprotein cholesterol (LDL-C) goal achievement in patients with Familial Hypercholesterolaemia (FH) <a href="#">Jessica Robin Johnson</a> (Sheffield)

---

---

P27

Facilitating the expansion of knowledge and skills in genomics for primary care practitioners in the context of Familial Hypercholesterolaemia

[Deborah Leetham](#) (Northumbria)

---

P28

Improving Education and Management of Cardiovascular Disease (CVD) Through a Primary Care Fellowship Programme – a South London Experience

[Kristina Leonnet](#) + [Margaret Connolly](#) (London)

---

P29

Familial Hypercholesterolaemia Detection rates – a comparison of a lipid clinic face to face model and pharmacist remote assessment

[Stewart Pattman](#) (North Sheilds)

---

P30

Lipoprotein (a) levels in elective cardiology admissions in a tertiary centre

[Alison Pottle](#) (London)

---

P31

From Rice to Risk Reduction: A successful home visit for FH cascade testing in a large Pakistani family

[Lorraine Priestley-Barnham](#) (Harefield)

---

P32

From struggle to success: Managing paediatric heterozygous familial hypercholesterolaemia with Evolocumab

[Lorraine Priestley-Barnham](#) (Harefield)

---

P33

Should Familial Hypercholesterolaemia (FH) be included in the NHS Newborn Genomes Programme ? Alignment with the four principles

[Uma Ramaswami](#) (London)

---

P34

Do monoclonal PCSK9 inhibitors cause transaminitis in established non-alcoholic fatty liver?

[Ruvini Ranasinghe](#) (London)

---

P35

The key to finding FH, is knowing where to look!

[Paula Sutton](#) (Yorkshire)

---

P36

Road to apheresis: Comprehensive management under one roof for accelerated coronary artery disease and its sequelae in a 45-year-old lady with raised Lipoprotein(a)

[Mahmud Tawil](#) (London)

---

P37

Familial chylomicronaemia: A rare life-threatening overlooked cause of raised triglycerides

[Mahmud Tawil](#) (London)

---

P38

Lipid optimisation in patients treated with tocilizumab infusion at a secondary care Rheumatology centre

[Catherine Tucker](#) (Northumbria)

---

P39

A case of lipid anomalies in cholestasis due to polycystic liver disease which resolved after liver transplantation

[Rajalakshmi Valaiyapathi](#) (London)

---

P40

Six Monthly Saviour: The organisation and implementation of a dedicated clinic for Inclisiran

[Susana Ramos Vazquez](#) (London)

---

P41

Review of Homozygous and Compound Heterozygous patient characteristics

[Julie Wagg](#) (London)

---